<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458405</url>
  </required_header>
  <id_info>
    <org_study_id>1002-01</org_study_id>
    <secondary_id>RC3HL103356-01</secondary_id>
    <nct_id>NCT01458405</nct_id>
  </id_info>
  <brief_title>Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration</brief_title>
  <acronym>ALLSTAR</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capricor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capricor Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells&#xD;
      (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial&#xD;
      infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    On February 28, 2019, Capricor ceased ongoing follow-up activities and terminated the ALLSTAR&#xD;
    trial to focus resourcing on its active CAP-1002 program, HOPE-2.&#xD;
  </why_stopped>
  <start_date type="Actual">November 13, 2012</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size assessed by MRI</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary safety endpoint is the proportion of patients that experience active myocarditis possibly attributable to treatment accompanied by the presence of circulating antibodies specific to the CAP-1002 CDC donor, death due to ventricular tachycardia or ventricular fibrillation, sudden unexpected death, or a major adverse cardiac event (MACE).&#xD;
The primary efficacy endpoint is relative percentage improvement in infarct size assessed by MRI for the CAP-1002 group compared to the placebo group at 12 months post-infusion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CAP-1002 Allogeneic Cardiosphere-Derived Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAP-1002 Allogeneic Cardiosphere-Derived Cells</intervention_name>
    <description>Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells</description>
    <arm_group_label>CAP-1002 Allogeneic Cardiosphere-Derived Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single, blinded, intracoronary infusion of a placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. History of MI (STEMI or NSTEMI) within the prior 12 months due to a coronary artery&#xD;
             event and evidenced by at least two of the following: typical ischemic symptoms,&#xD;
             serial ST-T changes (new ST elevation or new left bundle block) and/or elevated&#xD;
             troponin or CK-MB &gt;5 times the upper limit of normal. Also at least one of the&#xD;
             following: development of pathological Q wave ECG changes, imaging evidence of new&#xD;
             loss of viable myocardium, or new regional wall motion abnormalities.&#xD;
&#xD;
          2. History of percutaneous coronary intervention (PCI), with stent placement resulting in&#xD;
             TIMI flow = 3, in the coronary artery supplying the infarcted, dysfunctional territory&#xD;
             and through which the treatment will be infused.&#xD;
&#xD;
          3. At least one assessment of left ventricular ejection function (LVEF) ≤0.45 as&#xD;
             determined by any one of the standard modalities (echocardiography, ventriculography,&#xD;
             nuclear imaging, CT and/or MRI) prior to or during the screening period.&#xD;
&#xD;
               -  For subjects that fulfill the criteria of Recent MI (i.e., within 90 days of MI)&#xD;
                  at time of screening visit: assessment must be post-reperfusion after index MI&#xD;
                  and the most recent test prior to or during the screening period.&#xD;
&#xD;
               -  For subjects that fulfill the criteria of Chronic MI (i.e., greater than 90 days&#xD;
                  from MI) at the time of screening visit: assessment must be at least 21 days&#xD;
                  post-reperfusion after index MI and the most recent test prior to or during the&#xD;
                  screening period.&#xD;
&#xD;
             Note: subjects may screen as a Recent MI but be randomized into the Chronic MI strata&#xD;
             if the infusion date is &gt; 90 days post-MI.&#xD;
&#xD;
          4. Left ventricular infarct size of ≥ 15% of left ventricular mass in the qualifying&#xD;
             infarct-related region to be infused as determined by centrally read screening MRI,&#xD;
             with associated thinning and/or hypokinesis, akinesis, or dyskinesis, with no large&#xD;
             aneurysmal area in the infarcted regions.&#xD;
&#xD;
          5. No further revascularization clinically indicated at the time the subject is assessed&#xD;
             for participation in the clinical trial.&#xD;
&#xD;
          6. Ability to provide informed consent and follow-up with protocol procedures.&#xD;
&#xD;
          7. Age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects with a history of coronary artery bypass surgery, and a patent graft&#xD;
             (arterial or saphenous vein graft) attached to the coronary artery to be infused.&#xD;
&#xD;
          2. Diagnosed or suspected myocarditis.&#xD;
&#xD;
          3. History of cardiac tumor, or cardiac tumor demonstrated on screening MRI.&#xD;
&#xD;
          4. History of acute coronary syndrome in the 4 weeks prior to study infusion.&#xD;
&#xD;
          5. History of previous stem cell therapy.&#xD;
&#xD;
          6. History of radiation treatment to the central or left side of thorax.&#xD;
&#xD;
          7. Current or history (within the previous 5 years) of systematic auto-immune or&#xD;
             connective tissue disease including, but not limited to, giant cell myocarditis,&#xD;
             cardiac or systemic sarcoidosis, Dressler's syndrome, chronic recurrent or persistent&#xD;
             pericarditis.&#xD;
&#xD;
          8. History of or current treatment with immunosuppressive , anti-inflammatory, or other&#xD;
             agents to treat manifestations of systemic immunologic reactions, including chronic&#xD;
             systemic corticosteroids, biologic agents targeting the immune system, anti-tumor and&#xD;
             anti-neoplastic drugs, anti-VEGF, or chemotherapeutic agents within 3 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          9. Prior ICD and/or pacemaker placement where study imaging site has not been trained and&#xD;
             certified specifically for this protocol to conduct cardiac MRI in subjects with ICD&#xD;
             and/or pacemaker placement.&#xD;
&#xD;
             a. Presence of a pacemaker and/or ICD generator with any of the following&#xD;
             limitations/conditions are excluded: i. Manufactured before the year 2000, ii. Leads&#xD;
             implanted &lt; 6 weeks prior to signing informed consent, iii. Non-transvenous&#xD;
             epicardial, abandoned, or no-fixation leads, iv. Subcutaneous ICDs, v. Leadless&#xD;
             pacemakers, vi. Any other condition that, in the judgement of device-trained staff,&#xD;
             would deem an MRI contraindicated.&#xD;
&#xD;
             b. Pacemaker dependence with an ICD (Note: pacemaker-dependent candidates without an&#xD;
             ICD are not excluded).&#xD;
&#xD;
             c. A cardiac resynchronization therapy (CRT) device implanted &lt; 3 months prior to&#xD;
             signing informed consent.&#xD;
&#xD;
         10. Estimated glomerular filtration rate &lt; 30 mL/min.&#xD;
&#xD;
         11. Participation in an on-going protocol studying an experimental drug or device, or&#xD;
             participation in an interventional clinical trial within the last 30 days.&#xD;
&#xD;
         12. Diagnosis of arrhythmogenic right ventricular cardiomyopathy.&#xD;
&#xD;
         13. Current alcohol or drug abuse.&#xD;
&#xD;
         14. Pregnant/nursing women and women of child-bearing potential that do not agree to use&#xD;
             at least two forms of active and highly reliable method(s) of contraception.&#xD;
             Acceptable methods of contraception include contraceptive pills, depo-progesterone&#xD;
             injections, a barrier contraceptive such as a condom with or without spermicide cream&#xD;
             or gel, diaphragms or cervical cap with or without spermicide or gel, or an&#xD;
             intrauterine device (IUD).&#xD;
&#xD;
         15. Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         16. Viral hepatitis.&#xD;
&#xD;
         17. Uncontrolled diabetes (HbA1c&gt;9%).&#xD;
&#xD;
         18. Abnormal liver function (SGPT/ALT &gt; 3 times the upper reference range) and/or abnormal&#xD;
             hematology (hematocrit &lt; 25%, WBC &lt; 3000 µl, platelets &lt; 100,000 µl) studies without a&#xD;
             reversible, identifiable cause.&#xD;
&#xD;
         19. Sustained ventricular tachycardia (VT) or non-sustained ventricular tachycardia &gt; 30&#xD;
             beats, not associated with the acute phase of a previous MI (&gt; 48 hours after the MI&#xD;
             onset) or a new acute ischemic episode.&#xD;
&#xD;
         20. Ventricular fibrillation not associated with a new acute ischemic episode.&#xD;
&#xD;
         21. New York Heart Association (NYHA) Class IV congestive heart failure.&#xD;
&#xD;
         22. Evidence of tumor on screening chest/abdominal/pelvic (body) CT scan.&#xD;
&#xD;
         23. Any prior transplant.&#xD;
&#xD;
         24. Known hypersensitivity to dimethyl sulfoxide (DMSO).&#xD;
&#xD;
         25. Known hypersensitivity to bovine products.&#xD;
&#xD;
         26. Any malignancy within 5 years (except for in-situ non-melanoma skin cancer and in-situ&#xD;
             cervical cancer) of signing the ICF.&#xD;
&#xD;
         27. Any condition or other reason that, in the opinion of the Investigator or Medical&#xD;
             Monitor, would render the subject unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Litvack, MD</last_name>
    <role>Study Director</role>
    <affiliation>Capricor Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Heart - St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan CardioVascular Institute</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Heart and Vascular Institute / Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUMMA Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Heart and Vascular Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <disposition_first_submitted>October 5, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 5, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 9, 2018</disposition_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Stem cell</keyword>
  <keyword>Left ventricular dysfunction</keyword>
  <keyword>Congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

